Positives

• Mazdutide could be interesting to some chronic illness patients because GLP-1/glucagon medications are sometimes discussed in relation to metabolic inflammation, insulin resistance, appetite disruption, and weight changes after infection (Lancet eClinicalMedicine).
• If a patient has Long COVID plus significant glucose swings or metabolic syndrome, the mechanism may be worth discussing with a clinician, but this is not evidence that it treats PEM or brain fog (Nature).

Negatives

• The current evidence base is primarily about weight loss and diabetes markers, not improvements in PEM, dysautonomia, MCAS, Lyme, or fatigue (PMC).
• Decreased appetite, nausea, vomiting, diarrhea, and dehydration can be counterproductive for patients who already struggle to eat enough or maintain fluid and salt intake (PMC).

Hurdles & Side Effects

• Mazdutide is not a standard Long COVID or ME/CFS medication, and access depends on regulatory status and clinician willingness (Frontiers).
• Patients with POTS, gastroparesis-like symptoms, eating restriction, or medication sensitivity would need extra caution (PMC).